Oxydifficidin, a potent Neisseria gonorrhoeae antibiotic due to DedA assisted uptake and ribosomal protein RplL sensitivity
Curation statements for this article:-
Curated by eLife
eLife assessment
This useful study reports on the discovery of an antimicrobial agent that kills Neisseria gonorrhoeae. Sensitivity is attributed to a combination of DedA assisted uptake of oxydifficidin into the cytoplasm and the presence of a oxydifficidin-sensitive RpIl ribosomal protein. Due to the narrow scope, the broader antibacterial spectrum remains unclear and therefore the evidence supporting the conclusions is incomplete with key methods and data lacking. This work will be of interest to microbiologists and synthetic biologists.
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
Abstract
Gonorrhea, which is caused by Neisseria gonorrhoeae , is the second most prevalent sexually transmitted infection worldwide. The increasing appearance of isolates that are resistant to approved therapeutics raises the concern that gonorrhea may become untreatable. Here, we serendipitously identified oxydifficidin as a potent N. gonorrhoeae antibiotic through the observation of a Bacillus amyloliquefaciens contaminant in a lawn of N. gonorrhoeae . Oxydifficidin is active against both wild-type and multidrug-resistant N. gonorrhoeae . It’s potent activity results from a combination of DedA-assisted uptake into the cytoplasm and the presence of an oxydifficidin-sensitive ribosomal protein L7/L12 (RplL). Our data indicates that oxydifficidin binds to the ribosome at a site that is distinct from other antibiotics and that L7/L12 is uniquely associated with its mode of action. This study opens a potential new avenue for addressing antibiotic resistant gonorrhea and underscores the possibility of identifying overlooked natural products from cultured bacteria, particularly those with activity against previously understudied pathogens.
Article activity feed
-
-
-
Author response:
eLife assessment
This useful study reports on the discovery of an antimicrobial agent that kills Neisseria gonorrhoeae. Sensitivity is attributed to a combination of DedA assisted uptake of oxydifficidin into the cytoplasm and the presence of a oxydifficidin-sensitive RplL ribosomal protein. Due to the narrow scope, the broader antibacterial spectrum remains unclear and therefore the evidence supporting the conclusions is incomplete with key methods and data lacking. This work will be of interest to microbiologists and synthetic biologists.
General comment about narrow scope: The broader antibacterial spectrum of oxydifficidin has been reported previously (S B Zimmerman et al., 1987). The main focus of this study is on its previously unreported potent anti-gonococcal activity and mode of action. While it is true that …
Author response:
eLife assessment
This useful study reports on the discovery of an antimicrobial agent that kills Neisseria gonorrhoeae. Sensitivity is attributed to a combination of DedA assisted uptake of oxydifficidin into the cytoplasm and the presence of a oxydifficidin-sensitive RplL ribosomal protein. Due to the narrow scope, the broader antibacterial spectrum remains unclear and therefore the evidence supporting the conclusions is incomplete with key methods and data lacking. This work will be of interest to microbiologists and synthetic biologists.
General comment about narrow scope: The broader antibacterial spectrum of oxydifficidin has been reported previously (S B Zimmerman et al., 1987). The main focus of this study is on its previously unreported potent anti-gonococcal activity and mode of action. While it is true that broad-spectrum antibiotics have historically played a role in effectively controlling a wide range of infections, we and others believe that narrow-spectrum antibiotics have an overlooked importance in addressing bacterial infections. Their advantage lies in their ability to target specific pathogens without markedly disrupting the human microbiota.
We are troubled by the statement that our paper is narrow in scope and that evidence supporting our conclusions is incomplete. We do not feel the reviews as presented substantiate drawing this conclusion about our work.
Public Reviews:
Reviewer #1 (Public Review):
Summary:
Kan et al. report the serendipitous discovery of a Bacillus amyloliquefaciens strain that kills N. gonorrhoeae. They use TnSeq to identify that the anti-gonococcal agent is oxydifficidin and show that it acts at the ribosome and that one of the dedA gene products in N. gonorrhoeae MS11 is important for moving the oxydifficidin across the membrane.
Strengths:
This is an impressive amount of work, moving from a serendipitous observation through TnSeq to characterize the mechanism by which Oxydifficidin works.
Weaknesses:
(1) There are important gaps in the manuscript's methods.
The requested additions to the method describing bacterial sequencing and anti-gonococcal activity screening will be made. However, we do not think the absence of these generic methods reduces the significance of our findings.
(2) The work should evaluate antibiotics relevant to N. gonorrhoeae.
(1) It is not clear to us why reevaluating the activity of well characterized antibiotics against known gonorrhoeae clinical strains would add value to this manuscript. The activity of clinically relevant antibiotics against antibiotic-resistant N. gonorrhoeae clinical isolates is well described in the literature. Our use of antibiotics in this study was intended to aid in the identification of oxydifficidin’s mode of action. This is true for both Tables 1 and 2.
(2) If the reviewer insists, we would be happy to include MIC data for the following clinically relevant antibiotics: ceftriaxone (cephalosporin/beta-lactam), gentamicin (aminoglycoside), azithromycin (macrolide), and ciprofloxacin (fluoroquinolone).
(3) The genetic diversity of dedA and rplL in N. gonorrhoeae is not clear, neither is it clear whether oxydifficidin is active against more relevant strains and species than tested so far.
(1) We thank the reviewer for this suggestion. We aligned the DedA sequence from strain MS11 with DedA proteins from 220 N. gonorrhoeae strains that have high-quality assemblies in NCBI. The result showed that there are no amino acid changes in this protein. Using the same method, we observed several single amino acid changes in RplL. This included changes at A64, G25 and S82 in 4 strains with one change per strain. These sites differ from R76 and K84, where we identified changes that provide resistance to oxydifficidin. Notably, in a similar search of representative Escherichia, Chlamydia, Vibrio, and Pseudomonas NCBI deposited genomes, we did not identify changes in RplL at position R76 or K84.
(2) While the usefulness of screening more clinically relevant antibiotics against clinical isolates as suggested in comment 2 was not clear to us, we agree that screening these strains for oxydifficidin activity would be beneficial. We have ordered Neisseria gonorrhoeae strain AR1280, AR1281 (CDC), and Neisseria meningitidis ATCC 13090. They will be tested when they arrive.
Reviewer #2 (Public Review):
Summary:
Kan et al. present the discovery of oxydifficidin as a potential antimicrobial against N. gonorrhoeae, including multi-drug resistant strains. The authors show the role of DedA flippase-assisted uptake and the specificity of RplL in the mechanism of action for oxydifficidin. This novel mode of action could potentially offer a new therapeutic avenue, providing a critical addition to the limited arsenal of antibiotics effective against gonorrhea.
Strengths:
This study underscores the potential of revisiting natural products for antibiotic discovery of modern-day-concerning pathogens and highlights a new target mechanism that could inform future drug development. Indeed there is a recent growing body of research utilizing AI and predictive computational informatics to revisit potential antimicrobial agents and metabolites from cultured bacterial species. The discovery of oxydifficidin interaction with RplL and its DedA-assisted uptake mechanism opens new research directions in understanding and combating antibiotic-resistant N. gonorrhoeae. Methodologically, the study is rigorous employing various experimental techniques such as genome sequencing, bioassay-guided fractionation, LCMS, NMR, and Tn-mutagenesis.
Weaknesses:
The scope is somewhat narrow, focusing primarily on N. gonorrhoeae. This limits the generalizability of the findings and leaves questions about its broader antibacterial spectrum. Moreover, while the study demonstrates the in vitro effectiveness of oxydifficidin, there is a lack of in vivo validation (i.e., animal models) for assessing pre-clinical potential of oxydifficidin. Potential SNPs within dedA or RplL raise concerns about how quickly resistance could emerge in clinical settings.
(1) Spectrum/narrow scope: The broader antibacterial spectrum of oxydifficidin has been reported previously (S B Zimmerman et al., 1987). The focus of this study is on its previously unreported potent anti-gonococcal activity and its mode of action. While it is true that broad-spectrum antibiotics have historically played a role in effectively controlling a wide range of infections, we and others believe that narrow-spectrum antibiotics have an overlooked importance in addressing bacterial infections. Their advantage lies in their ability to target specific pathogens without markedly disrupting the human microbiota.
(2) Animal models: We acknowledge the reviewer’s insight regarding the importance of in vivo validation to enhance oxydifficidin’s pre-clinical potential. However, due to the labor-intensive process needed to isolate oxydifficidin, obtaining a sufficient quantity for animal studies is beyond the scope of this study. Our future work will focus on optimizing the yield of oxydifficidin and developing a topical mouse model for subsequent investigations.
(3) Potential SNPs: Please see our response to Reviewer #1’s comment 3. We acknowledge that potential SNPs within dedA and rplL raise concerns regarding clinical resistance, which is a common issue for protein-targeting antibiotics. Yet, as pointed out in the manuscript, obtaining mutants in the lab was a very low yield endeavor.
Reviewer #3 (Public Review):
Summary:
The authors have shown that oxydifficidin is a potent inhibitor of Neisseria gonorrhoeae. They were able to identify the target of action to rplL and showed that resistance could occur via mutation in the DedA flippase and RplL.
Strengths:
This was a very thorough and clearly argued set of experiments that supported their conclusions.
Weaknesses:
There was no obvious weakness in the experimental design. Although it is promising that the DedA mutations resulted in attenuation of fitness, it remains an open question whether secondary rounds of mutation could overcome this selective disadvantage which was untried in this study.
We thank the reviewer for the positive comment. We agree that investigating factors that could compensate for the fitness attenuation caused by DedA mutation would enhance our understanding of the role of DedA.
-
eLife assessment
This useful study reports on the discovery of an antimicrobial agent that kills Neisseria gonorrhoeae. Sensitivity is attributed to a combination of DedA assisted uptake of oxydifficidin into the cytoplasm and the presence of a oxydifficidin-sensitive RpIl ribosomal protein. Due to the narrow scope, the broader antibacterial spectrum remains unclear and therefore the evidence supporting the conclusions is incomplete with key methods and data lacking. This work will be of interest to microbiologists and synthetic biologists.
-
Reviewer #1 (Public Review):
Summary:
Kan et al. report the serendipitous discovery of a Bacillus amyloliquefaciens strain that kills N. gonorrhoeae. They use TnSeq to identify that the anti-gonococcal agent is oxydifficidin and show that it acts at the ribosome and that one of the dedA gene products in N. gonorrhoeae MS11 is important for moving the oxydifficidin across the membrane.
Strengths:
This is an impressive amount of work, moving from a serendipitous observation through TnSeq to characterize the mechanism by which Oxydifficidin works.
Weaknesses:
(1) There are important gaps in the manuscript's methods.
(2) The work should evaluate antibiotics relevant to N. gonorrhoeae.
(3) The genetic diversity of dedA and rplL in N. gonorrhoeae is not clear, neither is it clear whether oxydifficidin is active against more relevant strains …
Reviewer #1 (Public Review):
Summary:
Kan et al. report the serendipitous discovery of a Bacillus amyloliquefaciens strain that kills N. gonorrhoeae. They use TnSeq to identify that the anti-gonococcal agent is oxydifficidin and show that it acts at the ribosome and that one of the dedA gene products in N. gonorrhoeae MS11 is important for moving the oxydifficidin across the membrane.
Strengths:
This is an impressive amount of work, moving from a serendipitous observation through TnSeq to characterize the mechanism by which Oxydifficidin works.
Weaknesses:
(1) There are important gaps in the manuscript's methods.
(2) The work should evaluate antibiotics relevant to N. gonorrhoeae.
(3) The genetic diversity of dedA and rplL in N. gonorrhoeae is not clear, neither is it clear whether oxydifficidin is active against more relevant strains and species than tested so far.
-
Reviewer #2 (Public Review):
Summary:
Kan et al. present the discovery of oxydifficidin as a potential antimicrobial against N. gonorrhoeae, including multi-drug resistant strains. The authors show the role of DedA flippase-assisted uptake and the specificity of RplL in the mechanism of action for oxydifficidin. This novel mode of action could potentially offer a new therapeutic avenue, providing a critical addition to the limited arsenal of antibiotics effective against gonorrhea.
Strengths:
This study underscores the potential of revisiting natural products for antibiotic discovery of modern-day-concerning pathogens and highlights a new target mechanism that could inform future drug development. Indeed there is a recent growing body of research utilising AI and predictive computational informatics to revisit potential antimicrobial …
Reviewer #2 (Public Review):
Summary:
Kan et al. present the discovery of oxydifficidin as a potential antimicrobial against N. gonorrhoeae, including multi-drug resistant strains. The authors show the role of DedA flippase-assisted uptake and the specificity of RplL in the mechanism of action for oxydifficidin. This novel mode of action could potentially offer a new therapeutic avenue, providing a critical addition to the limited arsenal of antibiotics effective against gonorrhea.
Strengths:
This study underscores the potential of revisiting natural products for antibiotic discovery of modern-day-concerning pathogens and highlights a new target mechanism that could inform future drug development. Indeed there is a recent growing body of research utilising AI and predictive computational informatics to revisit potential antimicrobial agents and metabolites from cultured bacterial species. The discovery of oxydifficidin interaction with RplL and its DedA-assisted uptake mechanism opens new research directions in understanding and combating antibiotic-resistant N. gonorrhoeae. Methodologically, the study is rigorous employing various experimental techniques such as genome sequencing, bioassay-guided fractionation, LCMS, NMR, and Tn-mutagenesis.
Weaknesses:
The scope is somewhat narrow, focusing primarily on N. gonorrhoeae. This limits the generalizability of the findings and leaves questions about its broader antibacterial spectrum. Moreover, while the study demonstrates the in vitro effectiveness of oxydifficidin, there is a lack of in vivo validation (i.e., animal models) for assessing pre-clinical potential of oxydifficidin. Potential SNPs within dedA or RplL raise concerns about how quickly resistance could emerge in clinical settings.
-
Reviewer #3 (Public Review):
Summary:
The authors have shown that oxydifficidin is a potent inhibitor of Neisseria gonorrhoeae. They were able to identify the target of action to rpsL and showed that resistance could occur via mutation in the DedA flippase and RpsL.
Strengths:
This was a very thorough and clearly argued set of experiments that supported their conclusions.
Weaknesses:
There was no obvious weakness in the experimental design. Although it is promising that the DedA mutations resulted in attenuation of fitness, it remains an open question whether secondary rounds of mutation could overcome this selective disadvantage which was untried in this study.
-
